Lv1
10 积分 2024-06-28 加入
Case Study: Adefovir Dipivoxil: An Oral Prodrug of Adefovir
11小时前
待确认
MILLING OPERATIONS IN THE PHARMACEUTICAL INDUSTRY
1个月前
已完结
ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
1个月前
已完结
ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
1个月前
已关闭
Addressing the Complex Problem of Degradation‐Derived Mutagenic Impurities in Drug Substances and Products
2个月前
已完结
Addressing the Complex Problem of Degradation‐Derived Mutagenic Impurities in Drug Substances and Products
2个月前
已完结
Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals
4个月前
已完结
Genotoxic Threshold Mechanisms and Points of Departure
4个月前
已完结
Compound‐ and Class‐Specific Limits for Common Impurities in Pharmaceuticals
4个月前
已完结
Impurities in Oligonucleotide Drug Substances and Drug Products
6个月前
已完结
皖公网安备34019202002308
